Literature DB >> 7153100

Carcinoma of the esophagus: sites of failure.

R V Mantravadi, T Lad, H Briele, E J Liebner.   

Abstract

A clinico-pathologic study of 173 patients with esophageal cancer was done. The median survival for all patients was 6.4 months. Persistent tumor in esophagus at the time of death was present in 78% of patients treated with radiation alone. Metastases to mediastinal, intraabdominal and supraclavicular nodes were found in 73%, 49% and 20% of patients respectively. Systemic metastases were found in 57% of patients, liver being the most common site. In 15% of patients, fistulae developed between esophagus and trachea or bronchus because of direct extension of the primary tumor. Local and regional tumor caused the death of 111 patients, whereas distant metastases led to death in only 27 patients. This study confirms the extensive intra- and extrathoracic spread of malignancy in a majority of patients with cancer of the esophagus.

Entities:  

Mesh:

Year:  1982        PMID: 7153100     DOI: 10.1016/0360-3016(82)90447-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

Review 1.  Combined modality therapy for esophageal cancer.

Authors:  Z Gamliel; M J Krasna
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

Review 2.  [Radiotherapy in the multimodal treatment of esophageal carcinoma. A review].

Authors:  P Fritz; M Wannenmacher
Journal:  Strahlenther Onkol       Date:  1997-06       Impact factor: 4.033

Review 3.  Cancer of the esophagus: the Wayne State University experience.

Authors:  L Leichman
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

4.  Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer.

Authors:  M Albertsson; B Johansson; S Friesland; L Kadar; H Letocha; G Frykholm; G Wagenius
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.